Alterity Therapeutics Ltd (ATHE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has a cash flow conversion efficiency ratio of -0.192x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.43 Million) by net assets ($54.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alterity Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alterity Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Alterity Therapeutics Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Alterity Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alterity Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vivid Seats Inc
NASDAQ:SEAT
|
0.002x |
|
Panin Sekuritas Tbk
JK:PANS
|
0.079x |
|
Muda Holdings Bhd
KLSE:3883
|
0.000x |
|
Miko NV
BR:MIKO
|
0.072x |
|
Bookook Securities Co Ltd
KO:001275
|
-0.102x |
|
Korea Business News Co. Ltd
KQ:039340
|
0.015x |
|
High Co. SA
PA:HCO
|
0.078x |
|
PannErgy Nyrt.
F:PPL
|
0.173x |
Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Ltd from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see ATHE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $42.40 Million | $-11.45 Million | -0.270x | +70.44% |
| 2024-06-30 | $13.80 Million | $-12.61 Million | -0.914x | -4.02% |
| 2023-06-30 | $22.81 Million | $-20.04 Million | -0.878x | -152.49% |
| 2022-06-30 | $35.47 Million | $-12.34 Million | -0.348x | +38.84% |
| 2021-06-30 | $30.47 Million | $-17.33 Million | -0.569x | +36.39% |
| 2020-06-30 | $10.55 Million | $-9.43 Million | -0.894x | -6.07% |
| 2019-06-30 | $16.55 Million | $-13.95 Million | -0.843x | -117.06% |
| 2018-06-30 | $16.08 Million | $-6.25 Million | -0.388x | -56.86% |
| 2017-06-30 | $23.69 Million | $-5.87 Million | -0.248x | -4.68% |
| 2016-06-30 | $31.37 Million | $-7.42 Million | -0.237x | +14.91% |
| 2015-06-30 | $39.11 Million | $-10.87 Million | -0.278x | +24.04% |
| 2014-06-30 | $37.69 Million | $-13.79 Million | -0.366x | +35.69% |
| 2013-06-30 | $13.97 Million | $-7.95 Million | -0.569x | +53.26% |
| 2012-06-30 | $5.62 Million | $-6.85 Million | -1.217x | -85.11% |
| 2011-06-30 | $6.93 Million | $-4.56 Million | -0.658x | +26.97% |
| 2010-06-30 | $5.23 Million | $-4.71 Million | -0.900x | +51.72% |
| 2009-06-30 | $3.75 Million | $-6.99 Million | -1.865x | -95.95% |
| 2008-06-30 | $9.89 Million | $-9.41 Million | -0.952x | +41.93% |
| 2007-06-30 | $5.61 Million | $-9.20 Million | -1.639x | -22.82% |
| 2006-06-30 | $8.73 Million | $-11.66 Million | -1.335x | -129.03% |
| 2005-06-30 | $19.51 Million | $-11.37 Million | -0.583x | -321.78% |
| 2004-06-30 | $38.47 Million | $-5.31 Million | -0.138x | +39.11% |
| 2003-06-30 | $15.78 Million | $-3.58 Million | -0.227x | -0.44% |
| 2002-06-30 | $16.68 Million | $-3.77 Million | -0.226x | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more